OncologyTube Professional - Patients Click Here
401,354 video views
VJHemOnc: Videos
02:23
Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, talks about the collective organizational efforts to improve stem cell transplant therapies for the treatment of hematological cancers through a trials acceleration model. Prof. Craddock outlines prospective trials, including a randomized donor leukocy...
by:VJHemOnc | 94 views
02:06
Steven Treon, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, outlines the current outlook of Waldenström’s macroglobulinem​ia (WM), from “hand-me-down” to targeted approaches. The discovery of key growth and survival mutations, such as MYD88, has allowed the development of BTK inhibitors a...
by:VJHemOnc | 169 views
01:23
Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, updates us at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, on the results from the POLLUX trial (NCT02076009). Dr Usmani describes the o...
by:VJHemOnc | 265 views
01:22
Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, presents exciting results from clinical trials for bispecific antibodies targeting BCMA at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France. ...
by:VJHemOnc | 144 views
01:34
Approved monoclonal antibodies for multiple myeloma (MM) are currently available, yet there are still gaps to explore in this therapeutic area for MM. At the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France, Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, d...
by:VJHemOnc | 127 views
03:56
What is the current treatment landscape for plasma cell leukemia and extramedullary disease in multiple myeloma (MM)? We spoke to Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, about this at the European School of Haematology (ESH) International Conference on MM...
by:VJHemOnc | 93 views
02:23
The results of clinical trials are open to interpretation and are dependent upon a vast array of factors, including cohort size, the endpoints chosen and the statistics used to analyze the resulting date. Here, Robert Hills from the University of Oxford, Oxford, UK, discusses the most important considerations when judging the value of a clinical tr...
by:VJHemOnc | 29 views
02:20
Maria-Victoria Mateos, MD, PhD, of the University of Salamanca, Salamanca, Spain, discusses the updated analysis of the CASTOR trial (NCT02136134) with us at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France. This trial investigated...
by:VJHemOnc | 25 views
03:41
Multiple myeloma (MM) therapy has evolved rapidly in recent years, and is showing no sign of slowing. Here, Kenneth Anderson, MD, from Harvard Medical School, Boston, MA, discusses interesting future treatment combinations from the European School of Haematology (ESH) International Conference on MM 2018. Dr Anderson highlights a number of approache...
by:VJHemOnc | 14 views
02:50
Speaking from the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, Jesús San Miguel, MD, PhD, of the University of Navarra, Pamplona, Spain, discusses continuous and fixed duration therapy.
by:VJHemOnc | 8 views
dsfsd